RGNX240920P12500
- 1.10
- 0.000.00%
Regenxbio Newsroom
RegenXBio Appoints New EVP and CFO Amidst Key Developments
Express News | Regenxbio Inc - Vit Vasista Steps Down as CFO After 15 Years
Express News | Regenxbio Appoints Mitchell Chan as Chief Financial Officer
Press Release: REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $39 Price Target
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $39
H.C. Wainwright analyst Yi Chen maintains $Regenxbio(RGNX.US)$ with a buy rating, and maintains the target price at $39.According to TipRanks data, the analyst has a success rate of 27.9% and a
Positive Clinical Trials and Regulatory Milestones Bolster Buy Rating for RegenXBio
RegenxBio Touts Positive Data for Rare Disease Drug RGX-121
Express News | Regenxbio Inc - 80% of Patients Who Received Pivotal Dose Discontinued Intravenous Enzyme Replacement Therapy or Remained Treatment-Naïve
Express News | Regenxbio Inc - Submission of a Rolling Bla Using Accelerated Approval Pathway on Track for Q3 2024
Express News | Regenxbio Announces Positive Data From Pivotal Dose Level of Rgx-121 Demonstrating Long-Term Systemic Effect
REGENXBIO Announces Positive Data From Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
RegenXBio Grants RSUs to Executives Amidst Leadership Transition
Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $50
HC Wainwright & Co. Maintains Buy on Regenxbio, Raises Price Target to $39
Regenxbio Analyst Ratings